Albany Molecular Research (AMRI) Misses Q4 EPS by 5c; Guides FY15 EPS

Albany Molecular Research (NASDAQ: AMRI) reported Q4 EPS of $0.28, $0.05 worse than the analyst estimate of $0.33. Revenue for the quarter came in at $86.6 million versus the consensus estimate of $91.9 million.

Albany Molecular Research sees FY2015 EPS of $0.80-$0.90, versus the consensus of $0.90.

For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.

You May Also Be Interested In

• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
• Asana shares tumble on weak third quarter earnings outlook
• Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance